Clinical Trial Update: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight [Phase 3]

View source ↗

Summary

Phase 3 master protocol evaluating orforglipron in participants with obstructive sleep apnea and obesity/overweight; the study is currently active but not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Obstructive Sleep Apnea

Drugs mentioned

• Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: OSA, Overweight or Obesity | Phase 3 | Status: ACTIVE_NOT_RECRUITING